Indications

KANJINTI™ is a prescription medicine used for the treatment of:

  • Adjuvant breast cancer
    • KANJINTI™ is used for the treatment of early-stage breast cancer that is Human Epidermal growth factor Receptor 2-positive (HER2+) and that has spread into the lymph nodes, or is HER2-positive and has not spread into the lymph nodes. If it has not spread into the lymph nodes, the cancer needs to be estrogen receptor/progesterone receptor (ER/PR)-negative or have one high-risk feature. High risk is defined as ER/PR-positive with one of the following features: tumor size > 2 cm, age < 35 years, or tumor grade 2 or 3. ... Read More 
    • KANJINTI™ can be used in different ways:
      • As part of a treatment course including the chemotherapy drugs doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel. This treatment course is known as "AC → TH"
      • With the chemotherapy drugs docetaxel and carboplatin. This treatment course is known as "TCH"
      • Alone after treatment with multiple other therapies, including an anthracycline (doxorubicin) based therapy (a type of chemotherapy)
    • Patients are selected for therapy based on an FDA-approved test for trastuzumab.
  • Metastatic Breast Cancer
    • KANJINTI™ has 2 approved uses in metastatic breast cancer:
      • KANJINTI™ in combination with the chemotherapy drug paclitaxel is approved for the first line treatment of Human Epidermal growth factor Receptor 2-positive (HER2+) metastatic breast cancer
      • KANJINTI™ alone is approved for the treatment of HER2-positive breast cancer in patients who have received one or more chemotherapy courses for metastatic disease
    • Patients are selected for therapy based on an FDA-approved test for trastuzumab.
Asset 1

Whether you're a patient or a caregiver, we're here to help

If you’ve been prescribed KANJINTI™, you might have questions about how your medicine may be covered by your insurance. That’s why we created Amgen Assist 360™—to support you in every way we can, so you can focus on what’s most important to you.

AmgenAssist 360™

Whatever insurance you have—even if you have none—your Amgen Reimbursement Counselor can help you understand how KANJINTI™ may be covered, and can refer you to programs that may be able to help you afford it, such as Amgen FIRST STEP™.

Amgen Reimbursement Counselors can help you understand:
  • Insurance coverage
  • Co-pay costs
  • Deductible costs
Amgen FIRST STEP™
REFERRALS TO RESOURCES FOR DAY-TO-DAY LIVING*

We can help refer you to independent nonprofit organizations that may provide you with community resources, one-on-one counseling services, and local support groups.

To speak to an Amgen Reimbursement Counselor call 1‑888‑4ASSIST (888‑427‑7478) or visit AmgenAssist360.com.

Co-pay, Cost, and Insurance Coverage Assistance from Amgen

The Amgen FIRST STEP™ Program can help eligible commercially insured patients cover their out-of-pocket prescription costs, including deductible, co-insurance, and co‑payment.

  • $0 out-of-pocket for first dose
  • $5 out-of-pocket for subsequent doses, up to program maximum in assistance per calendar year. See AmgenFIRSTSTEP.com for terms and conditions
  • No income eligibility requirement

Call 1-888-65-STEP1 (1-888-657-8371) • Monday to Friday • 9:00 am to 8:00 pm ET or visit AmgenFIRSTSTEP.com.

The Amgen FIRST STEP™ Prepaid MasterCard is issued by Comerica Bank pursuant to license by MasterCard International Incorporated. No cash or ATM access. MasterCard is a registered trademark of MasterCard International Incorporated. This card can be used only to cover the co-payment for eligible prescriptions covered under the program at participating merchant locations where Debit MasterCard is accepted.


KANJINTI™ Breast Cancer Patient Brochure
Download this brochure to learn more about KANJINTI™

Links to the following organizations are provided for additional information and support, but should not be considered as an endorsement of KANJINTI™ by these organizations.

Helpful Resources for you throughout your treatment of Breast Cancer

Visit these websites for more information about breast cancer and support groups near you.

HELPFUL RESOURCES FOR YOU THROUGHOUT YOUR TREATMENT of Gastric cancer

Visit these websites for more information about gastric cancer and support groups near you.

*Resources include referrals to independent nonprofit patient assistance programs. Eligibility for resources provided by independent nonprofit patient assistance programs is based on the nonprofits’ criteria. Amgen has no control over these programs and provides referrals as a courtesy only.

Terms, conditions, and program maximums apply. This program is not open to patients receiving prescription reimbursement under any federal, state, or government-funded healthcare program. Not valid where prohibited by law.

Important Safety Information

What are the possible Serious Side Effects with KANJINTI™?

KANJINTI™ is not for everyone. Be sure to contact your doctor if you are experiencing any of the following potentially life threatening side effects:

HEART PROBLEMS
  • These include congestive heart failure or reduced heart function—with or without symptoms. The risk for and seriousness of these heart problems were highest in people who received both a trastuzumab product, like KANJINTI™, and a certain type of chemotherapy (anthracycline). In a study of adjuvant (early) breast cancer, one patient died of significantly weakened heart muscle. Your doctor will check for signs of heart problems before, during, and after treatment with KANJINTI™.
INFUSION REACTIONS, including:
  • Fever and chills
  • Feeling sick to your stomach (nausea)
  • Throwing up (vomiting)
  • Pain (in some cases at tumor sites)
  • Headache
  • Dizziness
  • Shortness of breath

These signs usually happen within 24 hours after receiving KANJINTI™.

Tell your doctor if you:
  • Are a woman who could become pregnant, or may be pregnant.
    • KANJINTI™ may result in the death of an unborn baby or birth defects.
    • Contraception should be used while receiving KANJINTI™ and for seven months after your last dose of KANJINTI™.
    • Tell your doctor right away if you are exposed to KANJINTI™ during pregnancy or within 7 months of becoming pregnant.
  • Have any signs of SEVERE LUNG PROBLEMS, including:
    • Severe shortness of breath
    • Fluid in or around the lungs
    • Weakening of the valve between the heart and the lungs
    • Not enough oxygen in the body
    • Swelling of the lungs
    • Scarring of the lungs
    • Your doctor may check for signs of severe lung problems
  • Have LOW WHITE BLOOD CELL COUNTS
    • Low white blood cell counts can be life threatening.
    • Low white blood cell counts were seen more often in patients receiving trastuzumab plus chemotherapy than in patients receiving chemotherapy alone.
    • Your doctor may test your blood and check for signs of low white blood cell counts.
What are the possible more common side effects of KANJINTI™?
Side Effects Seen most often with KANJINTI™
  • Some patients receiving trastuzumab products, like KANJINTI™, for breast cancer had the following side effects:
    • Fever
    • Feeling sick to your stomach (nausea)
    • Throwing up (vomiting)
    • Infusion reactions
    • Diarrhea
    • Infections
    • Increased cough
    • Headache
    • Feeling tired
    • Shortness of breath
    • Rash
    • Low white and red blood cell counts
    • Muscle pain
  • Some patients receiving trastuzumab products, like KANJINTI™, for metastatic stomach cancer had the following side effects:
    • Low white blood cell counts
    • Diarrhea
    • Feeling tired
    • Low red blood cell counts
    • Swelling of the mouth lining
    • Weight loss
    • Upper respiratory tract infections
    • Fever
    • Low platelet counts
    • Swelling of the mucous membranes
    • Swelling of the nose and throat
    • Change in taste

These are not all the possible side effects of KANJINTI™. For more information, ask your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.


Indications

KANJINTI™ is a prescription medicine used for the treatment of:

  • Adjuvant breast cancer
    • KANJINTI™ is used for the treatment of early-stage breast cancer that is Human Epidermal growth factor Receptor 2-positive (HER2+) and that has spread into the lymph nodes, or is HER2-positive and has not spread into the lymph nodes. If it has not spread into the lymph nodes, the cancer needs to be estrogen receptor/progesterone receptor (ER/PR)-negative or have one high-risk feature. High risk is defined as ER/PR-positive with one of the following features: tumor size > 2 cm, age < 35 years, or tumor grade 2 or 3.
    • KANJINTI™ can be used in different ways:
      • As part of a treatment course including the chemotherapy drugs doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel. This treatment course is known as "AC → TH"
      • With the chemotherapy drugs docetaxel and carboplatin. This treatment course is known as "TCH"
      • Alone after treatment with multiple other therapies, including an anthracycline (doxorubicin) based therapy (a type of chemotherapy)
    • Patients are selected for therapy based on an FDA-approved test for trastuzumab.
  • Metastatic Breast Cancer
    • KANJINTI™ has 2 approved uses in metastatic breast cancer:
      • KANJINTI™ in combination with the chemotherapy drug paclitaxel is approved for the first line treatment of Human Epidermal growth factor Receptor 2-positive (HER2+) metastatic breast cancer
      • KANJINTI™ alone is approved for the treatment of HER2-positive breast cancer in patients who have received one or more chemotherapy courses for metastatic disease
    • Patients are selected for therapy based on an FDA-approved test for trastuzumab.
  • Gastric Cancer
    • KANJINTI™ is approved, in combination with chemotherapy (cisplatin and either capecitabine or 5-fluorouracil), for the treatment of HER2-positive metastatic cancer of the stomach or gastroesophageal junction (where the esophagus meets the stomach) in patients who have not received prior treatment for their metastatic disease.
    • Patients are selected for therapy based on an FDA-approved test for trastuzumab.

Please see full Prescribing Information, including Boxed WARNINGS.

Herceptin® (trastuzumab) is a registered trademark of Genentech USA, Inc.